ASKC202

News alerts, weekly reports and conference planners

Company:

Aosaikang Pharma

Drug class:

c-MET inhibitor

Related drugs:

‹

›

ASKC202-001: Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 (clinicaltrials.gov)

P1, N=150, Recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Trial completion date: May 2025 --> Dec 2027 | Trial primary completion date: May 2024 --> Dec 2026

1 month ago

Trial completion date • Trial primary completion date

MET (MET proto-oncogene, receptor tyrosine kinase)

MET amplification

limertinib (ASK120067) • ASKC202

6ms

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy (clinicaltrials.gov)

P3, N=286, Not yet recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd.

6 months ago

New P3 trial

cisplatin • carboplatin • pemetrexed • limertinib (ASK120067) • ASKC202

almost3years

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 (clinicaltrials.gov)

P1, N=150, Recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: May 2022 --> Aug 2022

almost 3 years ago

Enrollment open • Trial initiation date • Metastases

MET (MET proto-oncogene, receptor tyrosine kinase)

MET amplification

ASKC202

almost4years

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 (clinicaltrials.gov)

P1, N=150, Not yet recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd.

almost 4 years ago

New P1 trial

MET (MET proto-oncogene, receptor tyrosine kinase)

MET amplification

ASKC202